BUY Aurobindo Pharma — Sachin Janardan Sarvade, 21 Sept 2026

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: Swing (≤2wk)21 Sept 2026via NDTV Profit (Live)

Entry₹1,709.8Inferred

Target₹2,000

Stop loss₹1,599-6.48% risk

CMP₹1,7004h ago

Active-0.57%+17.65%upside left 13d left

Follow Sachin Janardan Sarvade for new calls(17% target hit, 66 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 181 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 8:57 pm IST

9 supporting1 opposing

Supports the BUY call (9)

MACD above its signal line — bullish momentum

Technicals · macd·22 Sept · today

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · 6d ago

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 1w ago

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 1w ago

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 1w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Aurobindo Pharma — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

AI Assessment